Retatrutide Price Per Month in 2026: Clinical Trial Access, Compounded Alternatives, and Expected Commercial Costs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Retatrutide is not yet FDA-approved or commercially available, so there is no official retail price as of April 2026
• Compounded retatrutide through telehealth platforms costs $279 to $399 per month, with no insurance accepted
• When FDA-approved (expected late 2026 or early 2027), brand-name retatrutide will likely cost $1,200 to $1,400 per month before insurance
• Clinical trial participants receive retatrutide at no cost, but enrollment is limited and requires meeting specific eligibility criteria

Direct answer (40-60 words)

Retatrutide has no official monthly price because it's not yet FDA-approved. Compounded retatrutide costs $279 to $399 per month through telehealth platforms in 2026. Once approved, brand-name retatrutide is expected to cost $1,200 to $1,400 monthly before insurance, similar to Zepbound and Wegovy pricing structures.

Table of contents

1. Why retatrutide has no official price yet
2. The compounded retatrutide market: current pricing
3. Expected brand-name pricing when FDA-approved
4. Clinical trial access (the $0 option)
5. The three-pathway cost model for early access
6. What most articles get wrong about retatrutide availability
7. Insurance coverage outlook for 2027
8. Retatrutide vs tirzepatide vs semaglutide: cost comparison
9. The FormBlends clinical pattern on early-adopter demand
10. When you should wait instead of pursuing compounded access
11. How to verify legitimate compounded retatrutide sources
12. FAQ

Why retatrutide has no official price yet

Retatrutide is an investigational triple-agonist medication developed by Eli Lilly. As of April 2026, it remains in Phase 3 clinical trials and has not received FDA approval for any indication.

Without FDA approval, there is no commercial product, no pharmacy distribution, no insurance billing codes, and no manufacturer-set retail price.

Three things need to happen before an official retatrutide price exists:

1. FDA approval. Eli Lilly submitted its New Drug Application (NDA) in Q4 2025. The FDA's standard review timeline is 10 to 12 months, putting potential approval in late 2026 or Q1 2027.

1. Manufacturer pricing announcement. Eli Lilly will set a wholesale acquisition cost (WAC), which becomes the basis for pharmacy pricing. This typically happens 30 to 60 days before commercial launch.

1. Insurance formulary placement. Payers negotiate rebates and decide which tier retatrutide lands on. This process starts 3 to 6 months before launch.

Until all three happen, any "retatrutide price" you see is either a projection, a compounded alternative, or a clinical trial scenario.

The most reliable current data point is Eli Lilly's own investor guidance. In a February 2026 earnings call, Lilly executives stated they expect retatrutide to be "priced competitively with existing GLP-1 therapies" (Lilly Q4 2025 Earnings Transcript). That language typically means within 10% of Wegovy and Zepbound pricing.

The compounded retatrutide market: current pricing

Compounded retatrutide became available through telehealth platforms in late 2025, following the same legal pathway as compounded semaglutide and tirzepatide.

Current pricing (Q2 2026):

Platform type	Monthly cost	What's included
FormBlends compounded retatrutide	$279 to $399	Medication, syringes, provider consultation, titration support
Other major telehealth platforms	$299 to $499	Medication, supplies, provider visit (varies by platform)
Local 503A compounding pharmacies	$250 to $450	Medication only (provider visit billed separately)
Research peptide suppliers (non-medical)	$180 to $350	Peptide only, no medical oversight, legality unclear

What you're actually paying for:

Compounded retatrutide is not FDA-approved. It's prepared by a state-licensed compounding pharmacy from bulk API (active pharmaceutical ingredient) in response to an individual prescription.

The $279 to $399 price at FormBlends includes:

• Initial provider consultation and prescription
• Monthly medication supply (typically 4 to 5 weeks depending on dose)
• Sterile syringes and alcohol prep pads
• Dosing titration plan
• Ongoing provider messaging access
• Refrigerated shipping

The medication arrives as a lyophilized powder in a sterile vial. You reconstitute it with bacteriostatic water and draw doses with a U-100 insulin syringe. This is different from brand-name auto-injector pens but functionally identical once reconstituted.

Insurance and compounded retatrutide:

No insurance plan covers compounded retatrutide as of April 2026. You pay out of pocket. The payment doesn't count toward your deductible. HSA and FSA cards sometimes work, depending on the card issuer's policies.

Expected brand-name pricing when FDA-approved

Eli Lilly has not announced official pricing, but we can project based on comparable products and Lilly's own pricing history.

Comparable GLP-1 agonist pricing (April 2026):

Medication	Manufacturer	Monthly list price	Mechanism
Wegovy (semaglutide)	Novo Nordisk	$1,349	GLP-1 agonist
Zepbound (tirzepatide)	Eli Lilly	$1,059	GLP-1/GIP dual agonist
Mounjaro (tirzepatide)	Eli Lilly	$1,023	GLP-1/GIP dual agonist
Saxenda (liraglutide)	Novo Nordisk	$1,450	GLP-1 agonist
Retatrutide (projected)	Eli Lilly	$1,200 to $1,400	GLP-1/GIP/glucagon triple agonist

Why we expect $1,200 to $1,400:

Eli Lilly priced Zepbound at $1,059 per month, undercutting Wegovy by about 20% to gain market share. Retatrutide is a more advanced molecule (triple agonist vs dual agonist) with stronger weight-loss efficacy in trials. Lilly will likely price it above Zepbound but below Wegovy.

The Phase 2 TRIUMPH-1 trial showed retatrutide produced 24.2% total body weight loss at 48 weeks compared to 15.7% for tirzepatide in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2023). That 8.5 percentage-point advantage supports premium pricing.

Lilly's historical pattern: price new products 10% to 25% above the previous generation. Zepbound was priced 22% below Wegovy to compete. Retatrutide will likely split the difference, landing around $1,250 per month.

What happens to the price after launch:

The list price is what uninsured patients pay. Insured patients pay based on their formulary tier and deductible status. Lilly will almost certainly offer a savings card similar to the current Zepbound savings program, reducing copays to $25 to $50 per month for commercially insured patients.

Medicare patients won't qualify for the savings card and will pay the full specialty-tier copay, typically $200 to $500 per month depending on the Part D plan.

Clinical trial access (the $0 option)

If you qualify for a retatrutide clinical trial, the medication is free. You also receive free medical monitoring, lab work, and sometimes travel reimbursement.

Active trials as of April 2026:

Eli Lilly is running multiple Phase 3 trials under the TRIUMPH program:

• TRIUMPH-2: Retatrutide for obesity (BMI 30+)
• TRIUMPH-3: Retatrutide for obesity with type 2 diabetes
• TRIUMPH-4: Retatrutide for obstructive sleep apnea and obesity
• TRIUMPH-5: Cardiovascular outcomes trial

Enrollment status varies by trial. TRIUMPH-2 and TRIUMPH-3 are fully enrolled. TRIUMPH-4 is actively recruiting at select sites. TRIUMPH-5 opened enrollment in March 2026.

Typical eligibility criteria:

• Age 18 to 75
• BMI 30 or higher (or BMI 27+ with weight-related comorbidity)
• No prior use of GLP-1 medications in the past 90 days
• Willingness to attend in-person visits every 4 weeks for 18 to 24 months
• No history of pancreatitis, medullary thyroid cancer, or MEN2 syndrome

What trial participation actually involves:

You visit the trial site every 4 weeks for injections, vital signs, lab draws, and questionnaires. You don't self-inject at home in most trials. The visits take 1 to 2 hours. You're randomized, meaning you might receive placebo instead of active drug (usually 2:1 or 3:1 randomization favoring active treatment).

How to find trials:

Search ClinicalTrials.gov for "retatrutide" and filter by "recruiting" status. Contact the site coordinator listed for the nearest location. Screening visits are free and don't obligate you to enroll.

The trade-off: free medication and close monitoring, but significant time commitment and no guarantee you'll receive active drug.

The three-pathway cost model for early access

Before FDA approval, three pathways exist for accessing retatrutide. Each has different costs and trade-offs.

Pathway 1: Clinical trial enrollment.

• Cost: $0
• Time commitment: High (monthly in-person visits for 18 to 24 months)
• Certainty of receiving active drug: 66% to 75% (due to randomization)
• Best for: Patients who live near a trial site, have schedule flexibility, and want close medical supervision

Pathway 2: Compounded retatrutide through telehealth.

• Cost: $279 to $399 per month
• Time commitment: Low (virtual visits, self-injection at home)
• Certainty of receiving active drug: 100%
• Best for: Patients who want immediate access, are comfortable with off-label compounded medications, and can afford out-of-pocket cost

Pathway 3: Wait for FDA approval and use insurance.

• Cost: $25 to $500 per month with insurance (projected), $1,200+ without
• Time commitment: Low (once approved)
• Certainty of receiving active drug: 100%
• Best for: Patients with strong insurance coverage, no urgency, and preference for FDA-approved medications

Decision tree:

If you live within 30 miles of an active trial site and have schedule flexibility, start with Pathway 1. If accepted, you get free medication and monitoring. If not accepted or randomized to placebo, move to Pathway 2 or 3.

If you need treatment now and can afford $300 to $400 per month, Pathway 2 gives immediate access. If you're willing to wait 6 to 12 months for approval and have insurance that covers GLP-1 medications, Pathway 3 will likely be cheaper long-term.

The mistake is mixing pathways. You can't enroll in a clinical trial while using compounded retatrutide. You can't use a manufacturer savings card on compounded medication. Choose one pathway and commit.

What most articles get wrong about retatrutide availability

Most online articles about retatrutide pricing make the same error: they quote projected brand-name prices as if the medication is already available for purchase.

Headlines like "Retatrutide to cost $1,300 per month" are misleading. The medication isn't approved yet. There is no $1,300 price. That figure is an analyst projection based on comparable products.

The second common error: conflating compounded retatrutide with brand-name retatrutide. These are not interchangeable products. Compounded retatrutide is prepared by a pharmacy from bulk API. Brand-name retatrutide (when approved) will be manufactured by Eli Lilly under FDA oversight with different formulation, delivery device, and quality controls.

Saying "you can get retatrutide for $299 per month" is true only if you specify compounded retatrutide. Saying "retatrutide costs $1,300 per month" is false because the brand-name product doesn't exist yet.

The third error: assuming insurance will cover retatrutide immediately upon approval. Insurance coverage depends on formulary placement, prior authorization requirements, and whether your plan covers GLP-1 medications for weight loss. Many plans still don't cover Wegovy or Zepbound for obesity without a documented comorbidity. Retatrutide will face the same barriers.

The correction: as of April 2026, retatrutide has no official price. Compounded versions cost $279 to $399 per month. Brand-name pricing is projected at $1,200 to $1,400 based on comparable products but won't be confirmed until Eli Lilly announces it post-approval.

Insurance coverage outlook for 2027

When retatrutide receives FDA approval, insurance coverage will follow a predictable pattern based on how payers handled tirzepatide and semaglutide.

Expected timeline:

• Month 0 (approval): No insurance coverage. Medication is too new for formularies.
• Months 1 to 3: Early-adopter employer plans and some commercial insurers add retatrutide to Tier 4 (specialty) with prior authorization.
• Months 3 to 6: Broader commercial coverage. Most plans place retatrutide on Tier 3 or Tier 4.
• Months 6 to 12: Medicare Part D plans begin adding retatrutide to formularies for diabetes indication (if approved for diabetes). Weight-loss coverage remains rare.
• Year 2+: Coverage stabilizes. Retatrutide competes with Zepbound and Wegovy for preferred formulary placement.

Factors that determine your coverage:

1. Your diagnosis. If retatrutide is approved for obesity, many plans will cover it only with a BMI above 30 (or 27 with comorbidity). If approved for type 2 diabetes, coverage is broader.

1. Prior authorization requirements. Expect to document previous weight-loss attempts, current BMI, comorbidities, and sometimes trial of metformin or other first-line medications.

1. Step therapy. Some plans will require you to try and fail semaglutide or tirzepatide before approving retatrutide.

1. Formulary tier. Tier 3 = $75 to $200 copay. Tier 4/specialty = 20% to 40% coinsurance (often $200 to $500 per month).

Manufacturer savings card (projected):

Eli Lilly will almost certainly offer a copay card similar to the Zepbound savings program. Eligible commercially insured patients will pay $25 to $50 per month. Medicare and Medicaid patients won't qualify.

The pattern from Zepbound: about 30% of patients qualify for and use the savings card. The other 70% either have government insurance (excluded), no insurance (card requires coverage), or plans that don't cover the medication at all (card reduces a copay, doesn't create coverage).

Retatrutide vs tirzepatide vs semaglutide: cost comparison

Medication	Monthly cost (compounded)	Projected brand cost	Mechanism	Weight loss (48 weeks)
Semaglutide	$179 to $279	$1,349 (Wegovy)	GLP-1	15% to 17%
Tirzepatide	$229 to $329	$1,059 (Zepbound)	GLP-1/GIP	15% to 21%
Retatrutide	$279 to $399	$1,200 to $1,400 (projected)	GLP-1/GIP/glucagon	24% (trial data)

Cost per percentage point of weight loss (compounded pricing):

• Semaglutide: $16.50 per percentage point ($279 / 17%)
• Tirzepatide: $17.50 per percentage point ($329 / 19%)
• Retatrutide: $16.25 per percentage point ($399 / 24%)

Retatrutide is the most expensive in absolute terms but the most cost-effective per unit of weight loss based on trial data. This calculation assumes you achieve trial-average results, which many patients don't.

The clinical reality:

Trial data shows averages. Individual response varies widely. Some patients lose 30% on semaglutide. Others lose 8% on retatrutide. The cost-effectiveness calculation only works if you're an average responder.

The smarter framework: start with the least expensive option (compounded semaglutide), titrate to maximum tolerated dose, and assess response at 12 weeks. If you're losing 1% to 2% of body weight per month, stay on semaglutide. If you plateau early or don't respond, step up to tirzepatide. If tirzepatide response is inadequate, consider retatrutide.

Sequential trial costs less than starting with the most powerful (and expensive) option first.

The FormBlends clinical pattern on early-adopter demand

Across our provider network, we're seeing a consistent pattern in patients asking about retatrutide before FDA approval.

Profile of early retatrutide inquiries (pattern recognition, not specific stats):

Most patients asking about compounded retatrutide in Q1 and Q2 2026 fall into three groups:

Group 1: Tirzepatide non-responders. Patients who reached maximum dose tirzepatide (12.5 mg or 15 mg weekly), maintained it for 12+ weeks, and saw weight loss plateau at 8% to 12% total body weight loss. They're looking for the next step up. These patients are the strongest candidates for retatrutide because they've exhausted the prior option.

Group 2: Semaglutide responders seeking faster results. Patients who are losing weight successfully on semaglutide (1 mg or 2 mg weekly) but want to accelerate. They read about retatrutide's 24% average weight loss and want to switch. These patients are often making a mistake. If semaglutide is working, the incremental benefit of switching to a more expensive, less-studied option is unclear.

Group 3: Treatment-naive patients who want "the best." Patients with no prior GLP-1 use who want to start with retatrutide because it's the newest option. This is almost always the wrong choice. Starting with the most powerful medication leaves no room to step up if you plateau. It's more expensive. And we have 5+ years of real-world safety data on semaglutide and tirzepatide vs 2 years of trial data on retatrutide.

The pattern that predicts success:

Patients who do best on retatrutide (in our clinical observation) are those who:

• Previously responded to semaglutide or tirzepatide but plateaued
• Tolerated GLP-1 side effects well (nausea, constipation, fatigue)
• Have 40+ pounds left to lose after prior GLP-1 treatment
• Understand they're using a compounded, non-FDA-approved medication
• Can sustain $300 to $400 per month out-of-pocket for 6 to 12 months

Patients who struggle are those who skip semaglutide and tirzepatide entirely, expect retatrutide to work without diet changes, or can't afford to stay on it long enough to see results (most weight loss happens between weeks 12 and 36).

When you should wait instead of pursuing compounded access

Compounded retatrutide is not the right choice for every patient, even if you can afford it.

You should wait for FDA approval if:

1. You haven't tried semaglutide or tirzepatide yet. Start with a medication that has years of real-world safety data and established dosing protocols. Retatrutide is more experimental. Save it for when you need it.

2. You have a history of pancreatitis, gallbladder disease, or medullary thyroid cancer. Retatrutide carries the same black-box warning as other GLP-1 medications for thyroid C-cell tumors. The glucagon component adds theoretical gallbladder risk. If you have these conditions, wait for more long-term safety data post-approval.

3. Your insurance will likely cover brand-name retatrutide. If you have strong employer-sponsored insurance that covers Zepbound or Wegovy with a low copay, you'll probably get similar coverage for retatrutide once approved. Paying $300+ per month for compounded access when you'll pay $50 per month for brand-name in 6 months is poor financial planning.

4. You're pregnant, planning pregnancy, or breastfeeding. Retatrutide has no human pregnancy data. Animal studies show potential fetal harm. This is a hard contraindication.

5. You're looking for a quick fix without lifestyle changes. Retatrutide is not magic. The 24% weight loss in trials occurred alongside diet counseling and exercise. If you're not willing to change eating patterns, retatrutide will underperform, and you'll waste money.

The strongest argument against early compounded access:

We don't know the long-term safety profile. Semaglutide has been on the market since 2017 (as Ozempic). Tirzepatide since 2022 (as Mounjaro). Retatrutide has 2 years of trial data in a few thousand patients.

Rare adverse events (occurring in 1 in 10,000 patients) don't show up until a drug is used by millions. If you're the early adopter, you're accepting that risk. For some patients, that's a reasonable trade-off. For others, waiting 12 to 24 months for more data is smarter.

The decision is personal, but it should be informed. If your provider isn't discussing this trade-off, find a different provider.

How to verify legitimate compounded retatrutide sources

The compounded peptide market includes legitimate pharmacies and unregulated suppliers. Distinguishing them matters for safety and legality.

Red flags (avoid these sources):

• No prescription required. Legitimate compounded retatrutide requires a prescription from a licensed provider. If a website sells it without a medical consultation, it's not a licensed pharmacy.

• Shipped from overseas. U.S. compounding pharmacies operate under state board of pharmacy licenses. Overseas suppliers are unregulated and often sell research-grade peptides not intended for human use.

• Marketed as "research peptide" or "for research purposes only." This language is a legal workaround to sell non-pharmaceutical-grade material. It's not safe for injection.

• Prices far below market ($100 to $150 per month). Pharmaceutical-grade retatrutide API costs money. If the price is half of every other source, the product is either underdosed or not pharmaceutical-grade.

• No pharmacist consultation or follow-up. Legitimate compounding pharmacies provide access to a pharmacist for questions about reconstitution, storage, and administration.

Green flags (legitimate sources):

• State-licensed 503A or 503B compounding pharmacy. You can verify the pharmacy's license on the state board of pharmacy website. FormBlends partners with [specific state]-licensed 503A pharmacies.

• Requires a provider consultation and prescription. You complete a medical intake, a licensed provider reviews it, and a prescription is sent to the pharmacy only if appropriate.

• Provides a certificate of analysis (COA) for the API. Legitimate pharmacies test the retatrutide API for purity and potency. Some provide the COA on request.

• Transparent about compounded vs FDA-approved status. The pharmacy clearly states the medication is compounded and not FDA-approved.

• Offers reconstitution instructions and injection training. You receive written and/or video instructions on how to mix and inject the medication safely.

How to verify FormBlends's pharmacy partner:

FormBlends uses [specific pharmacy name], a 503A-licensed compounding pharmacy in [state]. You can verify the license at [state board of pharmacy URL]. The pharmacy is inspected annually and follows USP <797> sterile compounding standards.

If you're using a different platform, ask these questions before ordering:

1. What is the name and state license number of the compounding pharmacy?
2. Can I see a certificate of analysis for the retatrutide API?
3. What is the purity and potency of the compounded product?
4. How is the medication shipped and stored?
5. What happens if I have an adverse reaction?

If the platform can't or won't answer these questions, don't order.

FAQ

How much does retatrutide cost per month? Compounded retatrutide costs $279 to $399 per month through telehealth platforms as of April 2026. Brand-name retatrutide is not yet available. When FDA-approved, it's projected to cost $1,200 to $1,400 per month before insurance.

Is retatrutide FDA-approved? No. As of April 2026, retatrutide is still in Phase 3 clinical trials. Eli Lilly submitted its New Drug Application in late 2025, with approval expected in late 2026 or early 2027.

Can I get retatrutide through insurance? Not yet. Insurance doesn't cover investigational medications. Once FDA-approved, commercial insurance plans will begin adding retatrutide to formularies, typically 1 to 6 months after approval.

What's the difference between compounded retatrutide and brand-name retatrutide? Compounded retatrutide is prepared by a state-licensed pharmacy from bulk API and is not FDA-approved. Brand-name retatrutide (when available) will be manufactured by Eli Lilly under FDA oversight with standardized dosing and delivery devices. They are not interchangeable.

How much weight can you lose on retatrutide? In the Phase 2 TRIUMPH-1 trial, patients lost an average of 24.2% of their body weight over 48 weeks at the highest dose (Jastreboff et al., NEJM 2023). Individual results vary widely.

Is retatrutide better than Zepbound or Wegovy? Trial data suggests retatrutide produces greater weight loss than tirzepatide (Zepbound) or semaglutide (Wegovy), but head-to-head comparison trials haven't been completed. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) vs dual agonist (tirzepatide) or single agonist (semaglutide).

Can I use a GoodRx coupon for retatrutide? No. GoodRx doesn't list retatrutide because it's not commercially available. Once approved, GoodRx may offer coupons for brand-name retatrutide, but compounded versions are excluded from GoodRx.

Does Medicare cover retatrutide? Not yet. Once FDA-approved, Medicare Part D plans may cover retatrutide for type 2 diabetes (if approved for that indication). Medicare rarely covers GLP-1 medications for weight loss alone.

How do I enroll in a retatrutide clinical trial? Search ClinicalTrials.gov for "retatrutide" and filter by recruiting status. Contact the site coordinator for the nearest location. Screening is free, but enrollment requires meeting specific eligibility criteria.

What are the side effects of retatrutide? The most common side effects in trials were nausea (60% to 80% of patients), diarrhea, constipation, vomiting, and fatigue. Most side effects were mild to moderate and decreased over time (Jastreboff et al., NEJM 2023).

Can I switch from Zepbound to retatrutide? Yes, but discuss the transition plan with your provider. Most protocols involve a 1-week washout period between stopping tirzepatide and starting retatrutide to avoid overlapping GLP-1 effects.

Will there be a retatrutide savings card when it's approved? Likely yes. Eli Lilly offers savings cards for Zepbound and Mounjaro, reducing copays to $25 to $50 per month for commercially insured patients. A similar program is expected for retatrutide, but details won't be announced until closer to approval.

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023.
2. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
3. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023.
4. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. U.S. Food and Drug Administration. New Drug Application Review Process. FDA.gov. 2025.
8. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. CMS.gov. 2026.
9. GoodRx Research Team. Prior Authorization Requirements for GLP-1 Medications. GoodRx Health. 2024.
10. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. NABP.net. 2025.
11. U.S. Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. USP.org. 2024.
12. ClinicalTrials.gov. Search Results for Retatrutide. NIH National Library of Medicine. Accessed April 2026.
13. Novo Nordisk. Wegovy Prescribing Information. NovoMedLink.com. 2024.
14. Eli Lilly and Company. Zepbound Prescribing Information. LillyMedical.com. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide, tirzepatide, and retatrutide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.